Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
The chair of an inquiry into an alleged historical Westminster paedophile ring has been accused of 'editing' details of her impartiality.
There has been a sharp and worrying rise in the number of youngsters contacting ChildLine about suicide, the children's charity warned.
A travel firm will try to promote North Korea trips to UK holidaymakers - despite the country's current ban on visitors over Ebola fears.